博瑞医药涨2.06%，成交额1.18亿元，主力资金净流出390.74万元

Core Viewpoint - 博瑞医药's stock has shown significant volatility, with a year-to-date increase of 74.83%, but recent declines in the short term indicate potential challenges ahead [1][2]. Financial Performance - For the first half of 2025, 博瑞医药 reported revenue of 537 million yuan, a year-on-year decrease of 18.28%, and a net profit attributable to shareholders of 17.17 million yuan, down 83.85% compared to the previous year [2]. - Cumulative cash dividends since the A-share listing amount to 246 million yuan, with 129 million yuan distributed over the last three years [3]. Shareholder Information - As of June 30, 2025, 博瑞医药 had 9,568 shareholders, a decrease of 10.11% from the previous period, while the average number of circulating shares per person increased by 11.32% to 44,185 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which reduced its holdings by 1.0595 million shares to 3.2509 million shares, and a new entrant, Innovation Drug, holding 2.8126 million shares [3]. Market Activity - On October 21, 博瑞医药's stock price rose by 2.06% to 52.63 yuan per share, with a trading volume of 118 million yuan and a turnover rate of 0.54% [1]. - The stock experienced a net outflow of 3.9074 million yuan from main funds, with large orders showing a buy of 27.6355 million yuan and a sell of 30.5389 million yuan [1].